Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Henry Khederian

Here's Why Moderna Shares Are Rising On Monday

Moderna Inc (NASDAQ:MRNA) shares are trading higher by 18.9% at $164.27 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine.

According to Moderna, the primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. Moderna says the trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.

See Also: Here's Why Affirm Raised Guidance Today

Moderna has a 52-week high of $497.49 and a 52-week low of $117.34.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.